TYK2 and cancer: Second, the primary objective of these analyses was to evaluate safety profiles of TYK2 inhibition and, therefore, we did not include follow‐up assessment of potential pathophysiological mechanisms underpinning an effect of TYK2 inhibition on cancer risk.